Thompson Rubinstein Investment Management Inc. OR held its position in Allergan PLC. (NYSE:AGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,946 shares of the company’s stock at the end of the second quarter. Thompson Rubinstein Investment Management Inc. OR’s holdings in Allergan PLC. were worth $716,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Crestwood Advisors Group LLC bought a new position in Allergan PLC. during the first quarter valued at $103,000. Feltz Wealth PLAN Inc. bought a new position in Allergan PLC. during the first quarter valued at $107,000. Enterprise Financial Services Corp raised its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC raised its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded up 0.32% during trading on Monday, reaching $233.63. 510,883 shares of the company traded hands. The company’s 50-day moving average is $245.93 and its 200 day moving average is $238.13. The company has a market cap of $78.10 billion, a PE ratio of 7.12 and a beta of 1.16. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the prior year, the business earned $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.watchlistnews.com/thompson-rubinstein-investment-management-inc-or-maintains-stake-in-allergan-plc-nyseagn/1487536.html.

AGN has been the topic of several research reports. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Monday, June 12th. Mizuho decreased their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. UBS AG reissued a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Citigroup Inc. boosted their target price on shares of Allergan PLC. to $261.00 and gave the stock a “buy” rating in a research report on Monday, April 24th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Allergan PLC. has an average rating of “Buy” and an average price target of $275.49.

In related news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.36% of the stock is currently owned by corporate insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.